Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

New IMP building: International research center opens in Vienna

opening ceremony at IMP © IMP

Philipp von Lattorff explains that Boehringer Ingelheim, in its capacity as a family-owned company, has the financial means to support basic research which may first lead to the development of new drugs in the long run. “IMP is the most important investment of Boehringer Ingelheim in basic research”, says the Managing Director of Boehringer Ingelheim RCV.

About IMP

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by the international Boehringer Ingelheim group of companies With over 200 scientists from 40 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms in order to provide detail knowledge of complex biological phenomena. The IMP is a founding member of the Vienna Biocenter, Austria’s beacon in the international elite of top molecular-biological research.

About Boehringer Ingelheim Regional Center Vienna

The Boehringer Ingelheim Regional Center Vienna is responsible for Boehringer Ingelheim’s business with prescription drugs and animal medicines in Austria and over 30 other countries in Central and Eastern Europe, Central Asia, Switzerland and Israel. Moreover, the entire clinical research of the region is managed from Vienna. Vienna is the center for cancer research and also a location for biopharmaceutical research, development and production in the Group. Boehringer Ingelheim is also involved in basic research and is represented in this field by the Research Institute of Molecular Pathology Vienna (IMP). Thus, Boehringer Ingelheim is among Austria’s most research intensive pharmaceutical companies. The Regional Center Vienna generated net sales of EUR 760.2 million in the business year 2015 and employed 3,403 employees in the Central and Eastern European region, 1,501 of whom are in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Research and Found Your Company in Austria

    29.01.2020 / 16:30 - 18:00, Zurich, Switzerland

  • New Year's Reception

    29.01.2020 / 18:00, Zurich, Switzerland

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Turbocharger for the business location

The new Austrian Federal Government is committed to strengthening the economy, as shown in its programme, and has incorporated numerous measures to enhance the viability of Austria as a business location.

The new research allowance in Germany – in competition with the Austrian research tax credit?

Companies carrying out research and development in Austria have the possibility to apply for research funding, namely the so-called research tax credit. In an international comparison, the Austrian research tax credit is a recipe for success and is designed to showcase and enhance the attractiveness of Austria as a research location. The successive increase in the research tax credit from the original level of three percent in 2002 to 14 percent at present has made a massive contribution to this success.

More news All blog posts